News and Views
BioCryst Pharmaceuticals Hits Day Low of $6.00 Amid Price Pressure
2025-10-15 17:31:50BioCryst Pharmaceuticals, Inc. saw a notable stock decline, contrasting with the S&P 500's gains. The company reported positive operating cash flow and net sales of USD 163.35 million, but faces financial challenges, including a negative book value and a declining promoter stake. Year-to-date, the stock has decreased significantly.
Read More
BioCryst Pharmaceuticals Hits New 52-Week Low at $6.00
2025-10-15 16:35:44BioCryst Pharmaceuticals has hit a new 52-week low, trading at USD 6.00. The company, with a market cap of USD 1,719 million, has faced a performance dip over the past year. Despite a significant increase in operating profit and positive cash flow, promoter confidence has waned, complicating its market outlook.
Read More
BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility
2025-10-07 19:24:09BioCryst Pharmaceuticals, Inc. has seen its stock price decline to $7.02, down from $7.15. The company has experienced significant volatility over the past year, with a 52-week high of $11.31 and a low of $6.01. Current technical indicators suggest a bearish sentiment, and the stock has underperformed relative to the S&P 500.
Read MoreIs BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
2025-10-06 11:58:17As of 3 October 2025, the technical trend for BioCryst Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly and monthly MACD being bearish, as well as the Bollinger Bands and daily moving averages also signaling bearish trends. The KST shows a mixed signal with a weekly bearish and monthly bullish, while Dow Theory and OBV are both mildly bearish on a weekly and monthly basis. In terms of performance, the stock has underperformed against the S&P 500 across multiple periods, with a 1-week return of -6.29% compared to the S&P 500's 1.09%, and a 1-month return of -13.75% against the S&P 500's 4.15%. Over the past year, the stock is down -3.64% while the S&P 500 has gained 17.82%....
Read MoreIs BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
2025-10-05 11:43:11As of 3 October 2025, the technical trend for BioCryst Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, indicated by bearish MACD readings on both weekly and monthly time frames, bearish Bollinger Bands, and a bearish daily moving average. The KST shows a mixed signal with a bearish weekly and bullish monthly, while Dow Theory and OBV both reflect mildly bearish conditions on weekly and monthly bases. Over the past week, the stock has declined by 6.29%, significantly underperforming the S&P 500, which gained 1.09%. Over the past month, the stock is down 13.75% compared to the S&P 500's 4.15% gain, highlighting a persistent underperformance....
Read MoreIs BioCryst Pharmaceuticals, Inc. technically bullish or bearish?
2025-09-20 18:54:39As of 11 September 2025, the technical trend for BioCryst Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, with key indicators driving this assessment including a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on the weekly timeframe. Additionally, both the Dow Theory and OBV indicate a mildly bearish trend on the weekly and monthly scales. In terms of performance, the stock has underperformed compared to the S&P 500 over the past week and month, with returns of -1.36% and -5.01% respectively, while the S&P 500 gained 1.05% and 2.33%. However, year-to-date, the stock has a positive return of 5.85%, though it significantly lags behind the S&P 500's 12.22% return....
Read More
Announcement
Corporate ActionsCorporate Actions
